Piramal Enterprises gains on plans to acquire 5 injectable products from Janssen Pharmaceutica NV

10 Oct 2016 Evaluate

Piramal Enterprises is currently trading at Rs. 1877.00, up by 22.30 points or 1.20% from its previous closing of Rs. 1854.70 on the BSE.

The scrip opened at Rs. 1873.00 and has touched a high and low of Rs. 1880.00 and Rs. 1873.00 respectively.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2095.00 on 22-Aug-2016 and a 52 week low of Rs. 835.05 on 03-Mar-2016.

Last one week high and low of the scrip stood at Rs. 1927.75 and Rs. 1825.60 respectively. The current market cap of the company is Rs. 32,390.09 crore.

The promoters holding in the company stood at 51.58%, while Institutions and Non-Institutions held 30.80% and 17.63% respectively.

Piramal Enterprises’ wholly owned critical care subsidiary in the UK has entered into an agreement to acquire five anesthesia and pain management injectable products from Janssen Pharmaceutica NV, in an all cash deal for an upfront consideration of $155 million, and up to an additional $20 million. The products to be acquired are five injectable versions of well-established Janssen brands, Sublimaze (fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (alfentanil hydrochloride), Dipidolor (piritramide), and Hypnomidate (etomidate).

Piramal has agreed to acquire the brand names and all related IP as associated with the Products, including the know-how to make both the active pharmaceutical ingredients (API) and the finished dosage forms of the Products. The products are currently marketed in over 50 countries. The potential acquisition does not include the transfer of any manufacturing facilities or employees. The transaction is expected to close this week.

As part of the transaction, Janssen will continue to supply finished dosage forms for up to three years and API for up to five years. Janssen will continue to sell the products on behalf of Piramal until the marketing authorizations or relevant business relations are transferred to Piramal. Janssen can earn up to an additional $20 million if the Product portfolio achieves certain agreed financial milestones over the next 30 months.


Piramal Ent - Amalga Share Price

1124.60 0.00 (0.00%)
22-Sep-2025 16:59 View Price Chart
Peers
Company Name CMP
Bajaj Finance 989.30
Shriram Finance 979.15
Aditya Birla Capital 349.05
Chola Invest & Fin. 1702.15
Tata Capital 336.80
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×